ethyl 2-{ [(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylate hydrochloride | 1422435-39-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: ethyl 2-{ [(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylate hydrochloride
• 英文别名: ethyl 2-[[4-(aminoiminomethyl)phenylamino]methyl]-1-methyl-1H-benzimidazole-5-carboxylate hydrochloride；2-[[[4-(Aminoiminomethyl)phenyl]amino]methyl]-1-methyl-1H-benzimidazole-5-carboxylic Acid Ethyl Ester Hydrochloride；ethyl 2-[(4-carbamimidoylanilino)methyl]-1-methylbenzimidazole-5-carboxylate;hydrochloride
• CAS: 1422435-39-9
• 化学式: C₁₉H₂₁N₅O₂*ClH
• 分子量: 387.869
• InChiKey: OGAMNEWWGXWQOW-UHFFFAOYSA-N

物化性质

• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  3.07
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  106
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  氯甲酸正己酯 、 ethyl 2-{ [(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylate hydrochloride 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 以59%的产率得到去-(N-2-吡啶基-beta-丙氨酸乙酯)达比加群酯5-乙基羧酸酯
  参考文献：
  名称：

  Synthesis, Characterization and Suppression of Impurities during Optimization of Dabigatran Etexilate

  摘要：

  The synthetic methods for two impurities of dabigatran etexilate are firstly described, and both of two impurities are characterized by NMR and MS spectral data. The suppression of impurities as well as the optimization process of dabigatran etexilate is also disclosed.

  DOI：

  10.3987/com-13-12746
• 作为产物：
  描述：

  3-[[[2-[[(4-氰基苯基)氨基]甲基]-1-甲基-1H-苯并咪唑-5-基]羰基]吡啶-2-基氨基]丙酸乙酯 在 盐酸 、 氨 作用下， 以 乙醇 、 乙酸乙酯 为溶剂， 反应 44.0h， 生成 ethyl 2-{ [(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylate hydrochloride
  参考文献：
  名称：

  Synthesis, Characterization and Suppression of Impurities during Optimization of Dabigatran Etexilate

  摘要：

  The synthetic methods for two impurities of dabigatran etexilate are firstly described, and both of two impurities are characterized by NMR and MS spectral data. The suppression of impurities as well as the optimization process of dabigatran etexilate is also disclosed.

  DOI：

  10.3987/com-13-12746

文献信息

• [EN] NOVEL REFERENCE MARKERS OF DABIGATRAN ETEXILATE<br/>[FR] NOUVEAUX MARQUEURS DE RÉFÉRENCE D'ÉTÉXILATE DE DABIGATRAN
  申请人：ALEMBIC PHARMACEUTICALS LTD

  公开号：WO2013024394A1

  公开（公告）日：2013-02-21

  A new method of obtaining chemically pure and pharmaceutically acceptable Dabigatran Etexilate or its pharmaceutical acceptable salt having purity at least about 99% is provided, wherein the content of Dabigatran Etexilate individual impurity is less than 0.03-0.15% as measured by HPLC. A method of removing specific impurities that are generated either due to the intrinsic instability of Dabigatran Etexilate or in process of its preparation is provided too.

  提供了一种获得化学纯和药学可接受的达比加群胺乙酯或其药学可接受的盐的新方法，其纯度至少为约99％，其中达比加群胺乙酯个体杂质的含量小于0.03-0.15％，通过HPLC测量。还提供了一种去除特定杂质的方法，这些杂质是由达比加群胺乙酯的固有不稳定性或制备过程中产生的。